Protocol Ledger

NCT04799275 · Phase II/III · ACTIVE NOT RECRUITING

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Interventional Phase II/III clinical trial protocol NCT04799275 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-20 Enrollment: 422 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04799275
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)422 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04799275
Protocol FieldVerified Registry Value
NCT IdentifierNCT04799275
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment422 participants (ESTIMATED)
Registered Start Date2021-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI